For the China biotech industry, 2025 was a transformative year, marked by its emergence as a fast leader rather than merely a fast follower. This leap occurred despite a challenging domestic VC funding landscape and U.S. regulatory pressure.
The Out-licensing ExplosionThe most defining characteristic of 2025 was the boom i...